YI
111, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · CN
$3.14
+0.16%Year over year
Reported trailing growth
- Revenue
- -26.4%
- EBITDA
- —
- EBIT
- —
- EPS
- -39.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.3%
- EBITDA
- -92.6%
- EBIT
- —
- Net income
- +74.0%
- EPS
- +1.3%
- Free cash flow
- -53.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026